Incidence of and survival from malignant melanoma in Scotland: an epidemiological study

被引:163
作者
MacKie, RM [1 ]
Bray, CA
Hole, DJ
Morris, A
Nicolson, M
Evans, A
Doherty, V
Vestey, J
机构
[1] Univ Glasgow, Dept Dermatol, Glasgow G12 8QQ, Lanark, Scotland
[2] Univ Glasgow, Dept Publ Hlth, Glasgow G12 8QQ, Lanark, Scotland
[3] Ninewells Hosp, Dept Plast Surg, Dundee DD1 9SY, Scotland
[4] Ninewells Hosp, Dept Pathol, Dundee DD1 9SY, Scotland
[5] Foresterhill Hosp, Dept Oncol, Aberdeen, Scotland
[6] Royal Infirm, Dept Dermatol, Edinburgh, Midlothian, Scotland
[7] Raigmore Hosp, Dept Dermatol, Inverness, Scotland
关键词
D O I
10.1016/S0140-6736(02)09779-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background We aimed to assess the incidence and survival for all patients with invasive primary cutaneous malignant melanoma diagnosed in Scotland, UK, during 1979-98. Methods The Scottish Melanoma Group obtained data for 8830 patients (3301 male and 5529 female) first diagnosed with invasive cutaneous malignant melanoma. Findings Age-standardised incidence rose from 3.5 in 1979 to 10.6 per 10(5) population in 1998 for men, and from 7.0 to 13.1 for women, a rise of 303% and 187%, respectively. After 1995, the rate of increase levelled in women younger than 65 years at diagnosis. Melanoma incidence increased most in men on the trunk, head, and neck and in women on the leg. 5-year survival rose from 58% to 80% for men diagnosed in 1979 and 1993, respectively, and from 74% to 85% for women; improvements of 38% (p<0.001) and 15% (p<0.001), respectively. Most improvement was attributable to a higher proportion of thinner tumours. Male mortality from melanoma was 1-9/10(5) population per year at the start and end of the study, whereas mortality for men younger than 65 years at diagnosis rose from 1.2 to 1.35 (p=0.24). For all women, mortality fell slightly from 1.9 to 1.85/10(5) population per year (p=0.61), whereas for women younger than 65 years at diagnosis, mortality fell from 1.3 to 1.15 (p=0.62). Interpretation Interventions aimed at both primary and secondary prevention of melanoma are justified. Specialist tumour registers for entire countries can be used to plan and monitor public health interventions.
引用
收藏
页码:587 / 591
页数:5
相关论文
共 10 条
[1]   Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].
Balch, CM ;
Soong, SJ ;
Gershenwald, JE ;
Thompson, JF ;
Reintgen, DS ;
Cascinelli, N ;
Urist, M ;
McMasters, KM ;
Ross, MI ;
Kirkwood, JM ;
Atkins, MB ;
Thompson, JA ;
Coit, DG ;
Byrd, D ;
Desmond, R ;
Zhang, YT ;
Liu, PY ;
Lyman, GH ;
Morabito, A .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634
[2]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[3]  
Cohn-Cedermark G, 2000, CANCER-AM CANCER SOC, V89, P348, DOI 10.1002/1097-0142(20000715)89:2<348::AID-CNCR20>3.0.CO
[4]  
2-X
[5]  
Helliwell T, 2001, BRIT MED J, V322, P730
[6]   Recent trends in cutaneous melanoma incidence among whites in the United States [J].
Jemal, A ;
Devesa, SS ;
Hartge, P ;
Tucker, MA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (09) :678-683
[7]   CUTANEOUS MALIGNANT-MELANOMA, SCOTLAND, 1979-89 [J].
MACKIE, R ;
HUNTER, JAA ;
AITCHISON, TC ;
HOLE, D ;
MCLAREN, K ;
RANKIN, R ;
BLESSING, K ;
EVANS, AT ;
HUTCHEON, AW ;
JONES, DH ;
SOUTAR, DS ;
WATSON, ACH ;
CORNBLEET, MA ;
SMYTH, JF .
LANCET, 1992, 339 (8799) :971-975
[8]  
MACKIE RM, 1985, LANCET, V2, P859
[9]  
MacKie RM, 1997, BRIT MED J, V315, P1117, DOI 10.1136/bmj.315.7116.1117
[10]   Trends in the incidence of cutaneous malignant melanoma in New South Wales, 1983-1996 [J].
Marrett, LD ;
Nguyen, HL ;
Armstrong, BK .
INTERNATIONAL JOURNAL OF CANCER, 2001, 92 (03) :457-462